ALB and gastric cancer: This study (TACTIC GC-01) aimed to evaluate the efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as a second-line treatment for advanced gastric cancer (GC) following progression on programmed cell death protein 1 (PD-1) inhibitor-based therapy.